Description: Elagolix is a non-peptide, small-molecule, oral medication. It is a gonadotropin-releasing hormone (GnRH) receptor antagonist used to manage moderate to severe pain associated with endometriosis.

Indication: It is indicated for the management of moderate to severe pain associated with endometriosis in premenopausal women. Endometriosis is a condition where tissue similar to the lining of the uterus grows outside the uterus, causing pelvic pain and other symptoms.

Mechanism of Action (MOA): Elagolix works by acting as a competitive antagonist at the pituitary GnRH receptors. By binding to these receptors, it inhibits the release of gonadotropins, specifically luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The reduced levels of LH and FSH lead to a decrease in the production of ovarian sex hormones, primarily estradiol and progesterone. This dose-dependent suppression of estrogen helps to alleviate the pain and growth of endometrial tissue outside the uterus.